Global Osteoarthritis Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2015 to 2022

  • ID: 4313243
  • Report
  • Region: Global
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • Abiogen Pharma Spa
  • Eli Lilly and Company
  • Johnson & Johnson Limited
  • Merck & Co.
  • Novartis AG
  • MORE

The osteoarthritis treatment market was valued at USD 5,132.4 Mn in 2015, and is expected to reach USD 5,895.5 Mn by 2022, expanding at a CAGR of 1.95% from 2016 to 2022.

Market Insights
According to World Health Organization (WHO), Osteoarthritis (OA) is a long-term chronic disease characterized by the deterioration of cartilage in joints which results in bones rubbing together and creating stiffness, pain, and impaired movement. Furthermore, the disease most commonly affects the middle-aged and elderly, although younger people may be affected as a result of injury or overuse. Age is the strongest predictor of the disease and therefore increasing age and extended life expectancy will result in a greater occurrence of the disease. The meager treatment seeking rate is one of the main barriers to the growth of the market. Most of the medical practitioners suggested that early detection of osteoarthritis can improve patient’s quality of life but there is often a lack of awareness about the disease which requires attention. The types of therapeutics included in treatment of osteoarthritis disease are segmented as analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and hyaluronic acid. According to market experts, the non-steroidal anti-inflammatory drugs (NSAIDs) class of painkillers, such as diclofenac (150mg per day) and etoricoxib (30, 60 or 90mg per day) were found more likely to improve pain (between 95 and 100% likely) and were the top-ranked painkilling drugs. However, the major market restraint of NSAIDs market in osteoarthritis application is that its long-term use can trigger complications such as stomach ulcers, and, in rare cases may lead to heart failure.

Pipeline Analysis
The phase III drugs included in the pipeline analysis are Sprifermin (Merck Serono), Invossa (TissueGene), Ampion (Ampio Pharmaceuticals. Inc.),Apitox (Apimeds, Inc.), Fasinumab (Regeneron Pharmaceuticals), LBSA0103 (LG Life Sciences), and AXS-02 (Axsome Therapeutics, Inc.). According to market experts, it was observed that the late-stage development pipeline at present includes two drugs TissueGene’s Invossa and Merck Serono’s sprifermin which are expected to launch in the US in 2020 and 2021, respectively. The III phase clinical trials studies have shown evidence of reducing disease progression, and Invossa was also found to decrease osteoarthritis pain.

Key Market Movements

  • Osteoarthritis is mainly prevalent in elderly persons and a significant increase in osteoarthritis incidence has occurred over the past few years assisted by rapid increase in the obese population
  • Currently population of developed countries is at high risk of osteoarthritis due to increasing geriatric population
  • In developing countries from Asia Pacific and Latin America the awareness related to age-specific diseases such as osteoarthritis and osteoporosis is increasing
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • Abiogen Pharma Spa
  • Eli Lilly and Company
  • Johnson & Johnson Limited
  • Merck & Co.
  • Novartis AG
  • MORE
Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 Usp and Key Offerings
1.2 Research Methodology

Chapter 2 Executive Summary
2.1 Global Osteoarthritis Treatmentmarket Portaiture
2.2 Global Osteoarthritis Treatment Market, by Drugs, 2015 (USD Mn)
2.3 Relativity Analysis: Global Osteoarthritis Treatment Market, by Geography, 2015 & 2022 (USD Mn)

Chapter 3 Osteoarthritis Treatment Market: Market Dynamics and Outlook
3.1 Osteoarthritis Treatment Market Overview
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Osteoarthritis Treatment Market, 2015 (Value %)

Chapter 4 Global Osteoarthritis Treatment Market, by Type of Therapeutics
4.1 Preface
4.2 Analgesics
4.3 Non-Steroidal Anti-Inflammatory Drugs (Nsaids)
4.4 Corticosteroids
4.5 Hyaluronic Acid
4.6 Pipeline Analysis
4.6.1 Projected Sales of Phase III Drugs Estimated Till 2022 (US$ Mn)
4.6.1.1 Sprifermin
4.6.1.2 Invossa
4.6.1.3 Ampion
4.6.1.4 Apitox
4.6.1.5 Fasinumab
4.6.1.6 Lbsa0103
4.6.1.7 Axs-02
4.6.2 Tabular Representation of Phase II and I Drugs

Chapter 5 Global Osteoarthritis Treatment Market, by Geography
5.1 Preface
5.2 North America
5.2.1 U.S
5.2.2 Canada
5.3 Europe
5.3.1 U.K
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia Pacific
5.4.1 China
5.4.2 Japan
5.4.3 Rest of Asia Pacific
5.5 Rest of the World (Row)
5.5.1 Latin America
5.5.2 Middle East and Africa

Chapter 6 Company Profiles
6.1 Pfizer Inc
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
7.1.3 Product Portfolio
6.1.4 News Coverage
6.2 Novartis Ag
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Portfolio
6.2.4 News Coverage
6.3 Biodelivery Sciences International, Inc
6.3.1 Business Description
6.3.2 Financial Health and Budget Allocation
6.3.3 Product Portfolio
V.3.4 News Coverage
6.4 Abiogen Pharma Spa
6.4.1 Business Description
6.4.2 Financial Health and Budget Allocation
6.4.3 Product Portfolio
6.4.4 News Coverage
6.5 Johnson & Johnson Limited
6.5.1 Business Description
6.5.2 Financial Health and Budget Allocation
6.5.3 Product Portfolio
6.5.4 News Coverage
6.6 Abbott Laboratories
6.6.1 Business Description
6.6.2 Financial Health and Budget Allocation
6.6.3 Product Portfolio
6.6.4 News Coverage
6.7 Eli Lilly and Company
6.7.1 Business Description
6.7.2 Financial Health and Budget Allocation
6.7.3 Product Portfolio
6.7.4 News Coverage
6.8 Sanofi Sa
6.8.1 Business Description
6.8.2 Financial Health and Budget Allocation
6.8.3 Product Portfolio
6.8.4 News Coverage
6.9 Merck & Co
6.9.1 Business Description
6.9.2 Financial Health and Budget Allocation
6.9.3 Product Portfolio
6.9.4 News Coverage
6.10 Smith & Nephew, Inc
6.10.1 Business Description
6.10.2 Financial Health and Budget Allocation
6.10.3 Product Portfolio
6.10.4 News Coverage

List of Figures
Figure 1 Global Osteoarthritis Treatment Market, by Drugs, 2015 (USD Mn)
Figure 2 Relativity Analysis: Global Osteoarthritis Treatment Market, by Geography, 2015 & 2022 (USD Mn)
Figure 3 Attractive Investment Proposition, Global Osteoarthritis Treatment Market, 2015
Figure 4 Market Share Analysis: Global Osteoarthritis Treatment Market, 2015 (Value %)
Figure 5 Global Analgesics Market for Osteoarthritis Treatment, 2013 - 2022 (USD Mn)
Figure 6 Global Non-Steroidal Anti-Inflammatory Drugs (Nsaids) Market for Osteoarthritis Treatment, 20137- 2022 (USD Mn)
Figure 7 Global Corticosteroids Market for Osteoarthritis Treatment, 2013 -2022 (USD Mn)
Figure 8 Global Hyaluronic Acid Market for Osteoarthritis Treatment, 2013 - 2022 (USD Mn)
Figure 9 Pipeline Analysis: Global Sprifermin Market for Osteoarthritis Treatment, Upto 2022 (USD Mn)
Figure 10 Pipeline Analysis: Global Invossa Market for Osteoarthritis Treatment, Upto 2022 (USD Mn)
Figure 11 Pipeline Analysis: Global Ampion Market for Osteoarthritis Treatment, Upto 2022 (USD Mn)
Figure 12 Pipeline Analysis: Global Apitox Market for Osteoarthritis Treatment, Upto 2022 (USD Mn)
Figure 13 Pipeline Analysis: Global Fasinumab Market for Osteoarthritis Treatment, Upto 2022 (USD Mn)
Figure 14 Pipeline Analysis: Global Lbsa0103 Market for Osteoarthritis Treatment, Upto 2022 (USD Mn)
Figure 15 Pipeline Analysis: Global Axs-02 Market for Osteoarthritis Treatment, Upto 2022 (USD Mn)
Figure 16 U.S. Osteoarthritis Treatment Market Revenue, 2013 - 2022 (USD Mn)
Figure 17 Canada Osteoarthritis Treatment Market Revenue, 2013 - 2022 (USD Mn)
Figure 18 U.K Osteoarthritis Treatmentmarket Revenue, 2013 - 2022 (USD Mn)
Figure 19 Germany Osteoarthritis Treatment Market Revenue, 2013 - 2022 (USD Mn)
Figure 20 Rest of Europe Osteoarthritis Treatment Market Revenue, 2013 - 2022 (USD Mn)
Figure 21 China Osteoarthritis Treatment Market Revenue, 2013 - 2022 (USD Mn)
Figure 22 Japan Osteoarthritis Treatment Market Revenue, 2013 - 2022 (USD Mn)
Figure 23 Rest of Asia Pacific Osteoarthritis Treatment Market Revenue, 2013 - 2022 (USD Mn)
Figure 24 Latin America Osteoarthritis Treatment Market Revenue, 2013 - 2022 (USD Mn)
Figure 25 Middle East and Africa Osteoarthritis Treatment Market Revenue, 2013 - 2022 (USD Mn)

List of Tables
Table 1 Global Osteoarthritis Treatment Market Revenue, by Type of Therapeutics, 2013 - 2022 (USD Mn)
Table 2 Global Osteoarthritis Treatment Market Revenue, by Geography, 2013 - 2022 (USD Mn)
Table 3 North America Osteoarthritis Treatment Market Revenue, by Country, 2013 - 2022 (USD Mn)
Table 4 Europe Osteoarthritis Treatment Market Revenue, by Country, 2013 - 2022 (USD Mn)
Table 5 Asia - Pacific Osteoarthritis Treatment Market Revenue, by Country, 2013 - 2022 (USD Mn)
Table 6 Rest of the World Osteoarthritis Treatment Market Revenue, by Region, 2013 - 2022 (USD Mn)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Pfizer Inc.
  • Novartis AG
  • BioDelivery Sciences International, Inc.
  • Abiogen Pharma Spa
  • Johnson & Johnson Limited
  • Abbott Laboratories
  • Eli Lilly and Company
  • Sanofi SA
  • Merck & Co.
  • Smith & Nephew, Inc.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll